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ABSTRACT 
Commonly available therapeutic approaches for treating anemia of chronic kidney disease include oral iron supplementation such as ferrous 
fumarate, intra venous iron administration and erythropoiesis stimulating agents including erythropoietin, darbepoetin alfa, etc. Nowadays 
ESAs are used widely to treat anemia of chronic kidney disease and several studies have found that if used inappropriately it can even lead to  
cardiovascular diseases. The harmful effect of free iron in human body includes microbial growth promotion and free radical-induced reactions 
which can further cause deterioration of patient condition. Iron overload can lead to organ multiple organ failure in kidney disease patients. 
The iron level in the body is one of the significant factor for the effectiveness of erythropoietin. A well maintained iron homeostasis is required 
in the kidney disease patients to observe an effective treatment for anemia in chronic kidney disease patients. Lactoferrin, an iron-binding 
glycoprotein has been studied widely for its effect on iron homeostasis, anti-microbial activity, etc. Its safety and efficacy over other oral iron 
supplements have been established from several studies. This review article aims to support the need for further studies for attaining more vast 
knowledge regarding the use of lactoferrin in the treatment of anemia of chronic kidney disease. 
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Anemia is a condition characterized by a low level of 
hemoglobin in the blood which can be resulted from 
different underlying pathologies. As per the WHO definition, 
when hemoglobin levels fall from 13g/dL (in males) and 
12g/dL (in females) it can be considered as anemia, 
however, some individuals are apparently normal even if the 
hemoglobin level is less than this. Since oxygen carrying 
capacity of blood is related to hemoglobin, it decreases 
corresponding to low hemoglobin level. From several forms 
of anemia iron deficiency anemia is one of the commonest, 
and its high prevalence in underdeveloped countries is 
mostly contributed by low iron intake through diet, multiple 
pregnancies, parasitic infestations, etc. [1] 
Iron is an element highly essential for cell metabolism and 
growth, and is stored as ferritin and hemosiderin in the body 
(mostly in the liver). A major form of iron storage is ferritin. 
Iron forms complex with phosphate and hydroxide which is 
called as hemosiderin, when ferritin’s capacity exceeds. In 
serum, iron is bound to the iron transport protein called 
apotransferrin and the bound form is called transferrin. The 
main laboratory markers indicating iron status in the body 
are serum ferritin and transferrin saturation. The treatment 
option for iron deficiency anemia is chosen based on the 
severity of the disease, which includes supplementation of 
iron and erythropoiesis- stimulating factor. [2] 
CONVENTIONAL TREATMENTS 
After thorough examination and diagnosis of the patient 
condition and severity of anemia, the treatment should be 
provided aiming to normalize the hemoglobin concentration, 
red cell indices, and to replenish iron stores. Further steps 
should be chosen if the provided treatment is not effective. 
Iron supplementation along with treatment of the 
underlying cause can correct anemia and replenish body 
stores of iron. Oral iron supplementation is the first choice of 
treatment. Easily available, cheap and most widely used oral 
iron supplementation is ferrous fumarate. The 
Ironpolymaltose complex is another most frequently used 
oral iron preparation. In situations like a failure of oral iron 
to produce any response, lack of compliance, and/or 
intolerance to oral iron, a switch to intravenous iron therapy 
is recommended to provide efficient management of the 
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condition. Iron III saccharate and iron carboxymaltose are 
most commonly used iv iron preparations. In severe cases, 
recombinant erythropoietin is suggested in addition to 
suitable iron preparation. [3, 4, 5] 
LACTOFERRIN 
Lactoferrin is a member of the transferrin family of iron-
binding cationic glycoprotein, also called red protein. It has 
300 times more affinity for iron compared to transferrin and 
the red color is due to this iron binding property. It is 
synthesized within the human body by exocrine glands and 
neutrophils. Colostrum of milk is detected to have the 
highest level of lactoferrin and small amounts are also 
detected in nasal fluids, pancreatic juice, tears, saliva, 
gastrointestinal secretions, and reproductive tissue 
secretions. During infection and inflammation, its 
biosynthesis is expected to be increased. [6] 
From several studies regarding the functions of lactoferrin, it 
is found to be an emerging molecule with multiple functions 
in both physiological and pathological aspects, of which most 
important  functions include its role in intestinal iron 
homeostasis, role of supporting host defence mechanism 
against microbial infection, role as an anti-inflammatory 
agent, protective role against cancer development and 
metastasis and as a regulator of morphogenesis etc. for 
executing each function, several distinct mechanisms are 
involved.  
Pharmacokinetics and oral delivery of lactoferrin: 
A thorough knowledge on pharmacokinetic behaviour and 
effective route of administration is required for appropriate 
therapeutic application of lactoferrin. Several animal studies 
are conducted widely for this purpose. A study of In vivo 
kinetics and lactoferrin distribution in rats shown the rapid 
clearance from plasma followed by iv administration, thus 
showing a dose dependent pattern of clearance and 
distribution and In vivo degradation was gradual.[7,8] Some 
studies indicated the internalization of lactoferrin by rat 
hepatocytes, but some shown its uptake by endothelial and 
kupffer cells.[9,10] In a study where lactoferrin was 
administered through iv and intraperitonial route shown a 
preferential binding to the endothelial cells in the body, and 
its considerable concentration in lymphatic system shows its 
implication in anti-microbial therapy.[11] 
Since lactoferrin is a protein it can be degraded by the GI 
acids thus oral delivery of lactoferrin needs development of 
innovative technologies which should mainly focus on the 
stability maintenance and permeability to improve oral 
bioavailability. Chemical modification of lactoferrin with 
PEG showed increased GI stability and muco-adhesive 
chitosan shown to be with both enzyme inhibiting and 
absorption enhancing properties. Bioavailability of 
lactoferrin has been successfully enhanced by lipid based 
particulate carrier system. More effective and suitable oral 
drug delivery system should be developed through further 
research inorder to utilize the potential lactoferrin 
molecule.[12] 
Lactoferrin in treatment of anemia of chronic kidney 
disease: 
The total body iron content is distributed into functional and 
storage compartments. About 80% of the functional iron is 
found in hemoglobin; the rest is found in myoglobin and 
iron-containing enzymes. About 15% to 20% of total body 
iron is found in the storage pool which is represented by 
hemosiderin and ferritin. Iron is recycled within the body 
and is transported through the blood in bound form with 
transferrin, which is normally one third saturated with iron. 
This plasma transferrin delivers iron to cells and erythroid 
precursor for the synthesis of hemoglobin. In excess, free 
iron can be highly toxic and promote harmful processes such 
as microbial growth, free radical-induced cellular damage, 
etc. thus the iron should be in sequestered form for storage 
and iron homeostasis should be regulated thoroughly. 
Lactoferrin is thought to be involved in iron absorption from 
the intestine, although it has been a matter of debate over 
the years. [13,14] 
High bioavailability of iron and its abundant concentration 
in breast milk supports the role of lactoferrin in intestinal 
iron absorption. In addition, lactoferrin is relatively stable in 
gastric acid and resistant to proteolysis. [15]  
Several studies have shown the effectiveness of lactoferrin in 
the treatment of iron deficiency anemia. Natsue Koikawa et 
al. (2008) studied the preventive effect of lactoferrin intake 
on anemia in female long-distance runners and described 
the benefits of taking lactoferrin along with iron 
preparations. The ferritn, red blood cells count, and serum 
iron were significantly lower in group that only took iron 
suppliments, but there was no significant change in the 
group which were taking lactoferrin along with iron, thus 
inferred that lactoferirin can be useful in prevention of iron 
deficiency anemia.[16] Carmine Nappi et al. showed that 
bovine lactoferrin has the same efficacy in restoring iron 
deposits as ferrous sulphate in pregnant women with iron 
deficiency anemia with significantly fewer gastrointestinal 
side effects.[17] R. Paesano et al. (2010) described the efficacy 
of oral bovine lactoferrin in curing iron disorders in 
pregnant and non-pregnant women, and its effect on 
regulating iron homeostasis, also suggest the lactoferrin as 
an extremely valid natural drug, with few adverse effects, 
prevents and cures iron deficiency anemia more effectively 
than ferrous sulphate.[18] The same group conducted another 
study suggested that bovine lactoferrin represents a 
promising alternative to ferrous sulphate oral 
administration in treating iron deficiency anemia in 
pregnant women, with few adverse effects.[19] Rosalba 
Paesano et al. (2014) showed that lactoferrin is a 
significantly more effective option in curing iron deficiency 
anemia in pregnant women suffering from hereditary 
thrombophilia.[20,21] Mohamed Rezk et al. (2015) showed 
that lactoferrin helped to improve haemoglobin level than 
ferrous sulphate in treating iron deficiency anemia in 
pregnant women and it also states that a number of subjects 
in group receiving ferrous sulphate requested for a change 
of drug.[22,23] 
The prevalence of Anemia of chronic disease is more in 
patients suffering from any infections, chronic kidney 
disease, autoimmune disease or cancer. Low serum iron and 
preserved marrow iron, and Iron deficiency anemia are 
characteristic features of anemia of chronic kidney disease. 
Hypoferremia, Interleukin-6(IL-6), and hepcidin are 
interrelated factors which mediate the pathologic changes 
leading to ACD. Hepcidin plays a major role in mediating 
interactions between the immune system and iron 
metabolism. It is produced by hepatocytes. This peptide 
hormone acts as a key regulator of iron transport through 
the membranes, controls intestinal iron absorption, 
mobilization of stored iron in hepatocytes, and also controls 
the iron recycling by macrophages. Ferroportin is an iron 
exporter seen on macrophage, hepatocytes, and enterocytes, 
and it is the only known iron exporter in these cells. Efflux of 
iron through this iron exporter is inhibited by hepcidin. 
During inflammation or infection increased level of IL-6 
directly induces hepcidin synthesis which further leads to 
hypoferremia, thus for invading microorganisms, the plasma 
iron availability will be limited. However erythropoiesis 
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needs iron for hemoglobin synthesis, thus hypoferremia 
leads to Anemia associated with chronic disease. [24] 
Iron therapy with or without concomitant administration of 
erythropoiesis-stimulating agents has been used in the 
management of anemia in chronic kidney disease population 
for many years.  The Consideration for iron overload must 
be looked into, to prevent toxic and harmful effects of free 
iron. Oral administration of iron stimulates hepcidin 
synthesis which can lead to failure of iron supplements to 
cure ACD to an extent. In this respect, the novel and hopeful 
approach to treat ACD with lactoferrin in place of iron 
supplementation is of utmost importance. Lactoferrin 
chelates with two ferric ions per molecule, also down- 
regulation of inflammation reduces IL-6 production and 
independently reduce hepcidin gene expression thus helps 
to prevent hypoferrem+ia. From various studies in 
comparison to iron salts lactoferrin is found to have better 
compliance because of little or no gastrointestinal adverse 
effects which usually occur with normal iron supplements. 
[25,26,27] 
CONCLUSION 
Lactoferrin is a promising molecule with multiple functions 
including a role in maintaining iron homeostasis. It’s safety 
and efficacy in preventing and treating iron disorders have 
been proven from various studies and further studies should 
be conducted in order to obtain more vast knowledge 
regarding the use of lactoferrin to establish the value of 
lactoferrin over other existing treatment options for anemia 
of chronic disease. Development and application of new 
innovative technologies to improve the oral bioavailability of 
lactoferrin is necessary in order to explore more 
unidentified uses of the molecule, and to improve the 
efficacy in already established therapeutic effects. 
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